Advertisement

Current Infectious Disease Reports

, Volume 14, Issue 5, pp 474–483 | Cite as

Immune Aspects of Sepsis and Hope for New Therapeutics

  • Steven P. LaRosa
  • Steven M. OpalEmail author
Sepsis (J Russell, Section Editor)

Abstract

Marked alterations of the innate and adaptive immune response follow invasive infection and generalized inflammatory states. If left unchecked, this state of immune dysregulation contributes to a myriad of maladaptive cellular responses that culminate in multiple organ dysfunction, septic shock, and lethality. The molecular details of the cell-signaling networks that underlie the pathophysiology of systemic inflammation and sepsis are now increasingly well understood. While a vigorous and effective immune response to invasive pathogens is essential for microbial clearance and host survival, nonresolving, generalized inflammation can induce diffuse endovascular damage, increased capillary permeability, coagulopathy, and widespread tissue damage. Current evidence indicates that a state of relative immune suppression often accompanies sepsis and might provide novel therapeutic options in some patients. An expanding number of potential therapeutic options are now in clinical development to reestablish control and promote resolution over sepsis-induced systemic inflammation and organ dysfunction.

Keywords

Lipopolysaccharide Sepsis Septic shock Toll-like receptors Co-stimulatory immune signals Co-inhibitory immune signals Sepsis interventions Hemoperfusion Apheresis 

Notes

Disclosure

Dr. S. Opal has served as a consultant for Medimmune, Biotest, and Arsanis, received grant support for his institution fromAstra-Zenaca, Agennix, Asahi Kasel, David Horn LLC, Baxter, and Sirtris, and has served on data- and safety-monitoring boards for Sangart, Spectral Diagnostics, and Atoxio. Dr. S. LaRosa has served as a consultant for Ex Thera Medical and Agennix AG.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis. 2008;8:32–43.PubMedCrossRefGoogle Scholar
  2. 2.
    Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a Primer. Crit Care Med. 2009;37(1):291–304.PubMedCrossRefGoogle Scholar
  3. 3.
    •• Xiao W, Mindrinos MN, Seok J, et al. A genomic storm in critically injured humans. J Exp Med. 2011. doi: 10.1084/jem.20111354. This large study clearly demonstrates that the genes altered in acute systemic inflammation following severe injury follow similar patterns of upregulation and down regulation in patients that survive and those that do not survive. The differences in gene expression between survivors and non-survivors are primarily quantitative and not qualitative differences.
  4. 4.
    • Netea MG, van der Meer JWM. Immunodeficiency and genetic defects of pattern recognition receptors. N Engl J Med. 2011;464(1):60–70. This is an excellent review of the current state of knowledge about pattern recognition receptors, their microbial ligands, and the innate immune response to invasive pathogens.Google Scholar
  5. 5.
    Rathinam VAK, Jiang Z, Waggoner SN, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol. 2010;11(5):395–403.PubMedCrossRefGoogle Scholar
  6. 6.
    Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell. 2010;140:845–58.PubMedCrossRefGoogle Scholar
  7. 7.
    Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol. 2004;4:499–511.PubMedCrossRefGoogle Scholar
  8. 8.
    Beutler B. Inferences, questions and possibilities in toll-like receptor signaling. Nature. 2004;430:257–63.PubMedCrossRefGoogle Scholar
  9. 9.
    Visvanathan K, Charles A, Bannan J, Pugach P, Kashfi K, Zabriskie J. Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun. 2001;69:875–84.PubMedCrossRefGoogle Scholar
  10. 10.
    • Arad G, Levy R, Nasie I, et al. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biology. 2011;9:e1001149. This study elucidates the mechanism by which superantigens trigger the release of inflammatory cytokines resulting in septic shock.PubMedCrossRefGoogle Scholar
  11. 11.
    Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother. 2006;58(1):117–24.PubMedCrossRefGoogle Scholar
  12. 12.
    Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10:222–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296(5574):1880–2.PubMedCrossRefGoogle Scholar
  14. 14.
    Coughlin SR. Thrombin signaling and protease-activated receptors. Nature. 2000;407(6801):258–64.PubMedCrossRefGoogle Scholar
  15. 15.
    Tressel SL, Kaneider NC, Foley C, et al. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med. 2011;3:1–15.CrossRefGoogle Scholar
  16. 16.
    Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138–50.PubMedCrossRefGoogle Scholar
  17. 17.
    • Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. Tilting toward immunosuppression. Nat Med. 2009;15(5):496–7. This is a superb review of the problem of sepsis-induced immune suppression and the potential therapeutic options to restore immune function in these vulnerable patients.PubMedCrossRefGoogle Scholar
  18. 18.
    Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol. 2006;6:813–22.PubMedCrossRefGoogle Scholar
  19. 19.
    Hotchkiss RS, Opal SM. Immunotherapy for sepsis-A new approach against an ancient foe. N Engl J Med. 2010;361(1):87–9.CrossRefGoogle Scholar
  20. 20.
    •• Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594–605. This study provides compelling pathologic and immunologic evidence that sepsis-induced immune suppression is commonplace in septic patients and the dominant finding in human lethal septic shock.PubMedCrossRefGoogle Scholar
  21. 21.
    Rauch PJ, Chudnovskiy A, Robbins CS, et al. Innate response activator B cells protect against microbial sepsis. Science. 2012. doi: 10.1126/science.1215173.
  22. 22.
    Newell MK, Tobin RP, Cabrera JH, et al. TLR-mediated B cell activation results in ectopic CLIP expression that promotes B cell-dependent inflammation. J Leuk Biol. 2010;88:779–89.CrossRefGoogle Scholar
  23. 23.
    •• Nathan C, Ding A. Non-resolving inflammation. Cell. 2010;140:871–82. This is an excellent review of the critical elements that regulate the host response to human septic and sterile inflammatory processes. The mechanisms of immune and tissue-specific restoration of structure and function are examined in detail.PubMedCrossRefGoogle Scholar
  24. 24.
    Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med. 2006;354(11):1166–76.PubMedCrossRefGoogle Scholar
  25. 25.
    Kasten KR, Tschop J, Adediran SG, Hideman DA, Caldwell CC. T cells are potent early mediators of the host response to sepsis. Shock. 2010;34(4):327–36.PubMedCrossRefGoogle Scholar
  26. 26.
    Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 2010;107:1170–84.PubMedCrossRefGoogle Scholar
  27. 27.
    Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6:1191–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007; 869-74.Google Scholar
  29. 29.
    • Ballina-Rosas M, Olofsson PS, Ochanni M, et al. Acetylcholine-synthesizing T Cells relay neural signals in a vagus nerve circuit. Science. 2011;334:98–101. This work points out the intricate interactions between Vagus nerve signals and anti-inflammatory signals within the spleen that regulate cellular immune function.CrossRefGoogle Scholar
  30. 30.
    • Wong CHY, Jenne CN, Lee W-Y, Léger C, Kubes P. Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. Science. 2011;334:101–5. This remarkable study identifies the role of the sympathetic nervous system in regulating the function of NKT cells and the important contribution of these uncommon T cells to bacterial clearance.PubMedCrossRefGoogle Scholar
  31. 31.
    Mattsby-Baltzer I, Bergstrom T, McCrea K, et al. Affinity aphaeresis for treatment of bacteremia caused by Staphylococcus aureus and/or methicillin-resistant S. aureus (MRSA). J Microbiol Biotechnol. 2011;21(6):659–64.PubMedGoogle Scholar
  32. 32.
    • Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of Polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11:R47. This is a well performed meta-analysis of the randomized and non-randomized studies of the Polymyxin B immobilized filter. These results are the basis for the need for adequately powered, randomized, controlled clinical trial.PubMedCrossRefGoogle Scholar
  33. 33.
    Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock, the EUPHAS randomized controlled trial. JAMA. 2009;301:2445–52.PubMedCrossRefGoogle Scholar
  34. 34.
    Poelstra K, Bakker WW, Klok PA, et al. Dephosphorylation of endotoxin by alkaline phophatase in vivo. Am J Pathol. 1997;151:1163–9.PubMedGoogle Scholar
  35. 35.
    Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229–65.PubMedCrossRefGoogle Scholar
  36. 36.
    Verweij WR, Bentala H, van der Vlag AH, et al. Protection against an Escherichia coli- induced sepsis by alkaline phosphatase in mice. Shock. 2004;22:174–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Van Veen SQ, van Vliet AK, Wulferink M, et al. Bovine intestinal alkaline phosphatase attenuates the inflammatory response in secondary peritonitis in mice. Infect Immun. 2005;73:4309–14.PubMedCrossRefGoogle Scholar
  38. 38.
    Heemskerk S, Masereeuw R, Moesker O, et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med. 2009;37:417–23.PubMedCrossRefGoogle Scholar
  39. 39.
    • Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care. 2012;16:R14. This recently completed trial of alkaline phosphatase suggests that the benefit may be due to nephroprotective properties.PubMedCrossRefGoogle Scholar
  40. 40.
    Teleman D, Chung CS, Ayala A, et al. AB103, a CD28 antagonist peptide: a new therapeutic agent in a model of severe sepsis. Crit Care. 2011;15(3):35.CrossRefGoogle Scholar
  41. 41.
    Rice TW, Wheeler AP, Morris PE, et al. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine Fab for injection (CytoFab) in severe sepsis. Crit Care Med. 2006;34:2271–81.PubMedCrossRefGoogle Scholar
  42. 42.
    Yang H, Feldser H, Zhang W, et al. SIRT1 activators promote p65 deacetylation and suppress TNFα stimulated NF-κB activation. Abstract presented at the 2011 ASBMB Meeting in Washington D.C. in April 2011.Google Scholar
  43. 43.
    Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation. Available at http://clinicaltrials.gov/ct2/show/NCT01416376. Accessed 11 April 2012.
  44. 44.
    Zingarelli B, Cook JA. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock. 2005;23:393–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Collin M, Murch O, Thiemermann C. Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia. Crit Care Med. 2006;34:1131–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Kaplan JM, Denenberg A, Monaco M, et al. Changes in peroxisome proliferator-activated receptor-gamma activity in children with septic shock. Intensive Care Med. 2010;36:123–30.PubMedCrossRefGoogle Scholar
  47. 47.
    Kapoor A, Shintani Y, Collino M, et al. Protective role of peroxisome proliferator-activated receptor-β/б in septic shock. Am J Respir Crit Care Med. 2010;182:1506–15.PubMedCrossRefGoogle Scholar
  48. 48.
    • Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa activated in adults with septic shock. N Engl J Med. 2012;366:2055–64. This follow up study with recombinant human activated protein C failed to replicate improved survival in treated patients as observed in the original phase 3 trial. This drug has been taken off the market as a result of this study.PubMedCrossRefGoogle Scholar
  49. 49.
    Mohri M, Sugimoto E, Sata M, et al. The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation–a comparison with other anticoagulants. Thromb Haemost. 1999;82:1687–93.PubMedGoogle Scholar
  50. 50.
    Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31–41.PubMedCrossRefGoogle Scholar
  51. 51.
    Bhole D, Stahl GL. Therapeutic potential of targeting the complement cascade in critical care medicine. Crit Care Med. 2003;31(1 Suppl):S97–104.PubMedCrossRefGoogle Scholar
  52. 52.
    Guo RF, Riedemann NC, Ward PA. Role of C5a-C5aR interaction in sepsis. Shock. 2004;21:1–7.PubMedCrossRefGoogle Scholar
  53. 53.
    • Taylor FB, Kinasewitz GT, Lupu F. Pathophysiology, staging and therapy of severe sepsis in baboon models. J Cell Mol Med. 2012;16(4):672–82. This recently completed animal model of sepsis elucidates a second stage in sepsis whereby organ failure may be mediated by complement activation.PubMedCrossRefGoogle Scholar
  54. 54.
    Silasi-Mansat R, Zhu H, Popescu NI, et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood. 2010;116:1002–10.PubMedCrossRefGoogle Scholar
  55. 55.
    Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. Nat Med. 1999;5:788–92.PubMedCrossRefGoogle Scholar
  56. 56.
    Igonin AA, Protsenko DN, Gennadiy GM, et al. C1-esterase inhibitor infusion increases survival rates for patients with sepsis. Crit Care Med. 2012;40:770–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Weaver JG, Rouse MS, Steckelberg JM, Badley AD. Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis. FASEB J. 2004;18:1185–91.PubMedCrossRefGoogle Scholar
  58. 58.
    Unsinger J, McGlynn M, Kasten KR, et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol. 2010;184:3768–79.PubMedCrossRefGoogle Scholar
  59. 59.
    Inoue S, Unsinger J, Davis CG, et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction and improves survival in sepsis. J Immunol. 201;184 (3):1401-1409.Google Scholar
  60. 60.
    Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010;88:233–40.PubMedCrossRefGoogle Scholar
  61. 61.
    Albring JC, Sandau MM, Rapaport AS, et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. J Exp Med. 2010;207(12):2551–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Zhao G, Jin H, Li J, et al. PyNTTTTGT prototype oligonucleotide IMT504, a novel effective adjuvant of the FMDV DNA vaccine. Viral Immunol. 2009;22(2):131–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Laporte R, Kohan A, Heitzmann J, et al. Pharmacological characterization of FE 202158, a novel, potent, selective, and short acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension. JPET. 2011;337(3):786–96.CrossRefGoogle Scholar
  64. 64.
    • Cribbs S, Matthay MA, Martin GS. Stem cells in sepsis and acute lung injury. Crit Care Med. 2010;38:2379–85. An excellent review of the multiple mechanisms of action of adult human stem cells. The paper further summarizes the experience to date with adult stem cells in animal models of sepsis and acute lung injury.PubMedCrossRefGoogle Scholar
  65. 65.
    Mei SHJ, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010;182:1047–57.PubMedCrossRefGoogle Scholar
  66. 66.
    Krasnodembskaya A, Samarani G, Song Y, et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol 2012; in press.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Division of Infectious DiseaseBeverly HospitalBeverlyUSA
  2. 2.Infectious Disease DivisionThe Alpert Medical School of Brown UniversityProvidenceUSA
  3. 3.Infectious Disease DivisionMemorial Hospital of RIPawtucketUSA

Personalised recommendations